Likewise, PPA2 was associated with an increased risk of both aggressive and early onset disease, but lacked support from colocalisation analyses for prostate cancer risk overall [OROverall = 1.84, 95% CI: 1.52–2.22, PP4: 0.01; ORAggressive = 2.13, 95% CI: 1.54–2.93, PP4: 0.99; OREarly Onset = 2.70, 95% CI: 1.71–4.27, PP4: 0.93, Fig. 2, Supplementary Table S3]. This evidence concerns the gene PPA2 and prostate carcinoma.